NasdaqGS:ALNYBiotechs
Is It Time To Reconsider Alnylam Pharmaceuticals (ALNY) After Recent RNAi Progress And Volatile Price Moves
Wondering whether Alnylam Pharmaceuticals at around US$295.91 is offering fair value right now, or if the price is running ahead of the story? This article breaks down what the numbers suggest.
The stock has seen mixed returns with a 4.4% decline over the last 7 days and a 7.4% decline over 30 days, but it is still up 14.5% over 1 year, 43.6% over 3 years and 122.6% over 5 years.
Recent headlines have focused on Alnylam Pharmaceuticals' role in RNA interference based therapies and how its...